Cargando…

Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome

BACKGROUND: This analysis aimed to evaluate the impact of rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome (ACS) and to determine whether therapeutic drug monitoring might provide additional information regarding rivaroxaban do...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Liping, Yan, Xiaoyu, Nandy, Partha, Willmann, Stefan, Fox, Keith A. A., Berkowitz, Scott D., Sharma, Amarnath, Hermanowski-Vosatka, Anne, Schmidt, Stephan, Weitz, Jeffrey I., Garmann, Dirk, Peters, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669848/ https://www.ncbi.nlm.nih.gov/pubmed/31364490 http://dx.doi.org/10.1177/1753944719863641

Ejemplares similares

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
por: Zhang, Liping, et al.
Publicado: (2020)

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling
por: Solms, Alexander, et al.
Publicado: (2019)

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism
por: Reinecke, Isabel, et al.
Publicado: (2020)

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism
por: Solms, Alexander, et al.
Publicado: (2020)

Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations
por: Willmann, Stefan, et al.
Publicado: (2018)

A Cross‐Study Analysis Evaluating the Effects of Food on the Pharmacokinetics of Rivaroxaban in Clinical Studies
por: Zhang, Liping, et al.
Publicado: (2017)

Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease
por: Dagenais, Gilles R, et al.
Publicado: (2021)

Potential role of rivaroxaban in patients with acute coronary syndrome
por: Fitchett, David H
Publicado: (2012)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
por: Beyer-Westendorf, Jan, et al.
Publicado: (2019)

Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial
por: Branch, Kelley R., et al.
Publicado: (2019)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
por: Kubitza, Dagmar, et al.
Publicado: (2013)

Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
por: Leef, George C., et al.
Publicado: (2017)

Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban
por: Willmann, Stefan, et al.
Publicado: (2013)

Analysis of Effectiveness, Safety, and Bleeding Related to Rivaroxaban in Elderly Patients
por: Hou, Huimin, et al.
Publicado: (2020)

Resolution of Extensive Coronary Thrombosis under Rivaroxaban Treatment
por: Yuksel, Murat, et al.
Publicado: (2015)

Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older
por: Ageno, Walter, et al.
Publicado: (2021)

Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
por: Spyropoulos, Alex C., et al.
Publicado: (2020)

Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications
por: Kubitza, Dagmar, et al.
Publicado: (2016)

Intracranial Hemorrhage in Patient Treated with Rivaroxaban
por: Molina, Michelle, et al.
Publicado: (2014)

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Rationale and Design of Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation (REWRAPS)
por: Ozaki, Yukio, et al.
Publicado: (2022)

Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed
por: Zhou, Dao, et al.
Publicado: (2022)

Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease
por: Willmann, Stefan, et al.
Publicado: (2022)

Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
por: Rawal, Shalin, et al.
Publicado: (2022)

Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study
por: Li, Ying, et al.
Publicado: (2020)

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
por: Willmann, Stefan, et al.
Publicado: (2021)

Rivaroxaban Rebound Acute Coronary Event: A Post Marketing Experience
por: Agarwal, Ajay, et al.
Publicado: (2013)

Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice
por: Shivu, Ganesh Nallur, et al.
Publicado: (2014)

Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease
por: Cowie, Martin R, et al.
Publicado: (2020)

Benefit and risk of adding rivaroxaban in patients with coronary artery disease: A systematic review and meta‐analysis
por: Xie, Cheng, et al.
Publicado: (2020)

Measurement of rivaroxaban and apixaban in serum samples of patients
por: Harenberg, Job, et al.
Publicado: (2014)

Initial rivaroxaban dosing in patients with atrial fibrillation
por: Ablefoni, Kaja, et al.
Publicado: (2019)

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation
por: Kim, Paul Y., et al.
Publicado: (2018)

Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF
por: Sharma, Abhinav, et al.
Publicado: (2023)

Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
por: Raskob, Gary E., et al.
Publicado: (2022)

Exploring the opinions and experiences of patients with generic substitution: a representative study of Polish society
por: Drozdowska, Aleksandra, et al.
Publicado: (2014)

Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden
por: Begum, Najida, et al.
Publicado: (2015)

Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings
por: Arashi, Hiroyuki, et al.
Publicado: (2022)

Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial
por: Piccini, Jonathan P., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9atm9lphj0fdef4lr3ubul9p13